摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-[4-(1-Amino-1-methylethyl)phenyl]-5-cyano-N-{4-[2-piperidin-1-ylethyl]phenyl}pyrimidine-2-amine

中文名称
——
中文别名
——
英文名称
4-[4-(1-Amino-1-methylethyl)phenyl]-5-cyano-N-{4-[2-piperidin-1-ylethyl]phenyl}pyrimidine-2-amine
英文别名
4-[4-(2-aminopropan-2-yl)phenyl]-2-[4-(2-piperidin-1-ylethyl)anilino]pyrimidine-5-carbonitrile
4-[4-(1-Amino-1-methylethyl)phenyl]-5-cyano-N-{4-[2-piperidin-1-ylethyl]phenyl}pyrimidine-2-amine化学式
CAS
——
化学式
C27H32N6
mdl
——
分子量
440.591
InChiKey
JNXPMOFMEZVEGM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4
  • 重原子数:
    33
  • 可旋转键数:
    7
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.37
  • 拓扑面积:
    90.9
  • 氢给体数:
    2
  • 氢受体数:
    6

反应信息

  • 作为产物:
    描述:
    4-[4-(1-tert-butoxycarbonylamino-1-methylethyl)phenyl]-5-cyano-N-[4-(2-piperidin-1-ylethyl)phenyl]pyrimidine-2-amine 、 trifluoracetic acid-dichloromethane 在 二氯甲烷碳酸氢钠magnesium sulfate 作用下, 反应 0.5h, 以to give the title compound (240 mg) as a yellow solid, m.p. 150°的产率得到4-[4-(1-Amino-1-methylethyl)phenyl]-5-cyano-N-{4-[2-piperidin-1-ylethyl]phenyl}pyrimidine-2-amine
    参考文献:
    名称:
    5-Cyano-2-aminopyrimidine derivatives
    摘要:
    描述了化学式(1)的嘧啶类化合物,其中Ar是可选取代的芳香族或杂环芳香族基团;R1是氢原子或直链或支链烷基;R2是—X1—R3基团,其中X1是直接键或连接原子或基团,R3是可选取代的脂肪族、环状脂肪族、杂原子脂肪族、杂环脂肪族、芳香族或杂环芳香族基团;以及其盐、溶剂合物、水合物和N-氧化物。这些化合物是选择性KDR激酶和/或FGFr激酶抑制剂,可用于预防和治疗与血管生成相关的疾病状态。
    公开号:
    US20040180914A1
点击查看最新优质反应信息

文献信息

  • 5-cyano-2-aminopyrimidine derivatives
    申请人:——
    公开号:US20020147339A1
    公开(公告)日:2002-10-10
    Pyrimidines of formula (1) are described 1 wherein Ar is an optionally substituted aromatic or heteroaromatic group; R 1 is a hydrogen atom or a straight or branched chain alkyl group; R 2 is a —X 1 —R 3 group where X 1 is a direct bond or a linker atom or group, and R 3 is an optionally substituted aliphatic, cycloaliphatic, heteroaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are selective KDR Kinase and/or FGFr Kinase inhibitors and are of use in the prophylaxis and treatment of disease states associated with angiogenesis.
    公式(1)中描述了嘧啶类化合物,其中Ar是可选择取代的芳香或杂芳基团;R1是氢原子或直链或支链烷基基团;R2是一个—X1—R3基团,其中X1是直接键或连接原子或基团,而R3是可选择取代的脂肪、环脂肪、杂原子脂肪、杂环脂肪、芳香或杂芳基团;以及它们的盐、溶剂合物、水合物和N-氧化物。这些化合物是选择性的KDR激酶和/或FGFr激酶抑制剂,并可用于预防和治疗与血管生成相关的疾病状态。
  • [EN] 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES<br/>[FR] DERIVES DE 5-CYANO-2-AMINOPYRIMIDINE
    申请人:CELLTECH CHIROSCIENCE LTD
    公开号:WO2000078731A1
    公开(公告)日:2000-12-28
    Pyrimidines of formula (1) are described wherein Ar is an optionally substituted aromatic or heteroaromatic group; R1 is a hydrogen atom or a straight or branched chain alkyl group; R2 is a -X1-R3 group where X1 is a direct bond or a linker atom or group, and R3 is an optionally substituted aliphatic, cycloaliphatic, heteroaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are selective KDR Kinase and/or FGFr Kinase inhibitors and are of use in the prophylaxis and treatment of disease states associated with angiogenesis.
    描述了式(1)的嘧啶类化合物,其中Ar是可选择的取代芳香族或杂环芳香族基团;R1是氢原子或直链或支链烷基;R2是-X1-R3基团,其中X1是直接键或连接原子或基团,R3是可选择的取代脂肪族、环状脂肪族、杂原子脂肪族、杂环脂肪族、芳香族或杂环芳香族基团;以及其盐、溶剂合物、水合物和N-氧化物。这些化合物是选择性的KDR激酶和/或FGFr激酶抑制剂,可用于预防和治疗与血管生成相关的疾病状态。
  • 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES
    申请人:Celltech R&D Limited
    公开号:EP1187816A1
    公开(公告)日:2002-03-20
  • Modeling of systemic inflammatory response to infection
    申请人:Vitiello Antonia Maria
    公开号:US20070083333A1
    公开(公告)日:2007-04-12
    Models for the systemic inflammatory response to infection, which involve the use of immunocompromised animals, and methods of using the models are described. These models can be used in identifying analytes or biomarker panels that can be used in staging or monitoring sepsis. The models can also be used for predicting an animal's disease outcome or in providing a prognosis for sepsis patients. Further, the invention relates to methods for evaluating potential treatments for sepsis.
  • US6579983B1
    申请人:——
    公开号:US6579983B1
    公开(公告)日:2003-06-17
查看更多